Published in

Nephrology (Saint-Petersburg), 2(24), p. 22-41, 2020

DOI: 10.36485/1561-6274-2020-24-2-22-41

Elsevier, Kidney International, 2(95), p. 268-280, 2019

DOI: 10.1016/j.kint.2018.10.018

Links

Tools

Export citation

Search in Google Scholar

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Journal article published in 2019 by Jürgen Floege, Sean J. Barbour, Daniel C. Cattran, Jonathan J. Hogan, Patrick H. Nachman, Sydney C. W. Tang, Jack F. M. Wetzels, Sharon G. Adler, Michael Cheung, Charles E. Alpers, Isabelle Ayoub, David C. Wheeler, Arvind Bagga, Wolfgang C. Winkelmayer ORCID, Jonathan Barratt and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline’s publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.